OM
CATX icon

Opaleye Management’s Perspective Therapeutics CATX Stock Holding History

Opaleye Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$834K Buy
+200,000
New +$845K 0.11% 50

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Opaleye Management's CATX Position: Q1 2026 in Review

Opaleye Management increased its Perspective Therapeutics (CATX) stake by 295% in Q1 2026, buying an estimated $14.7M and bringing the position to 4,675,000 shares worth $19.5M. The position accounts for 2.57% of the portfolio, ranked #11.

Opaleye Management first reported a position in CATX in Q4 2025 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Opaleye Management held 4,675,000 shares of Perspective Therapeutics worth $19.5M as of Q1 2026.
  • Opaleye Management bought 3,490,500 Perspective Therapeutics shares in Q1 2026, an estimated $14.7M.
  • Perspective Therapeutics made up 2.57% of Opaleye Management's portfolio in Q1 2026, its #11 holding.
  • Opaleye Management first reported a position in Perspective Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.